No Data
Sawai GHD inherits the rights to warfarin tablets in the country.
On the 27th, Sawai GHD <4887.T> announced that the group's Sawai Pharmaceutical has signed a contract to inherit the rights to the pharmaceutical product Warfarin Tablets (generic name: Warfarin Potassium), manufactured and sold by Eisai <4523.T> in Japan. The oral anticoagulant "Warfarin" has been used for a long time in the treatment and prevention of many patients with thromboembolic diseases. With the conclusion of the contract, the company will pay Eisai 45 as compensation for the transfer.
Eisai To Go Ex-Dividend On March 28th, 2025 With 80 JPY Dividend Per Share
March 27th (Japan Standard Time) - $Eisai(4523.JP)$ is trading ex-dividend on March 28th, 2025.Shareholders of record on March 31st, 2025 will receive 80 JPY dividend per share. The ex-dividend date
Eisai, Taiyo Yuden, ETC [List of stock materials from the newspaper]
*V Technology <7717> enters laser dicing, aiming for practical use next year (Nikkan Kogyo, front page) -○ *Kanadevia <7004> implements measures to prevent recurrence of marine engine fuel economy fraud (Nikkan Kogyo, page 3) -○ *Eisai <4523> plans to reduce 30 billion yen by FY2026, optimizing the organization (Nikkan Kogyo, page 3) -○ *Petroleum Resource Development <1662> sells its UK subsidiary for 33.6 billion yen in oil field development (Nikkan Kogyo, page 4) -○ *ENEOSHD <5020> ENEOS produces lubricants and more at the Yokohama plant.
Angle's Breast Cancer Assay Shows Real-time Monitoring Promise in Mid-stage Pilot Study
ANGLE Plc Completes Key Assay Developments and Eisai Contract
Angle PLC Announces Results of Eisai Phase 2 Pilot Study
